UPDATED: 10.23.09 @ 7 AM EDT -- The "Hall Pass" was granted, this morning in Brussels. Now we await US FTC/DoJ clearance, and then -- as I indicated below, the Intervet Call Option fireworks. [The original posting of this item was 10.22.09 @ 2:26 PM EDT.]
If -- at around 4 a.m. EDT, tomorrow morning -- the right hand margin of this ECC Journal link contains an "en", with a live-link attached to it, you'll know that the European Competition Commission has officially granted the deal (the Merck/Schering-Plough reverse merger portion, anyway) a "hall pass".
This pass will be good until the Sanofi-Merial 100-day call option (on the Intervet businesses) is exercised -- then the "competition review fun" will begin in earnest:
. . . .18 September 2009
Prior publication in Official Journal
Provisional deadline: 23 October 2009. . . .
Of course -- even if the ECC is wholly-obliging tomorrow morning, our time -- that still leaves the US FTC/DoJ HSR process to contend with.